The distribution of coronavirus vaccines in low-income countries may soon be greatly promoted.On Thursday, two sources familiar with the matter told Reuters that Pfizer (New York Stock Exchange: PFE) with Biological Technology (Nasdaq stock code: BNTX) It has been agreed to provide a plan co-led by the World Health Organization (WHO) and its COVID-19 vaccine.
The COVAX project is a work coordinated by WHO, the Alliance for Epidemic Preparedness Innovation (CEPI) and the vaccine alliance Gavi. The goal of the plan is to obtain 2 billion doses by the end of this year to protect vulnerable populations and frontline medical personnel in participating countries. All countries are eligible, but the program plans to provide about 1
The details of the number of doses that Pfizer and BioNTech have agreed to and the price per dose that COVAX plans to pay to partners remain unclear. Neither company has officially announced an agreement to supply COVAX, but they are expected to fill the gap on Friday.
In some countries/regions, this will not be the first vaccine protected by the COVAX program.In December, COVAX plans to AstraZeneca (Nasdaq: AZN) Approved 170 million doses of coronavirus drug candidates for use in the UK and India. Johnson (New York Stock Exchange: JNJ) In addition, the company has reached an agreement with the plan to provide 500 million doses of a single-dose candidate vaccine, which is expected to generate late-stage clinical trial data on any day.